Abstract
Fluoropyrimidine drugs (5 flurouracil (5 FU) capecitabine) are the backbone of therapeutic regimens for digestive carcinomas and can lead to severe toxicities. To lower that risk, the French health authorities recommend dose adaptation based on plasma uracil concentration. Since dihydro pyrimidine dehydrogenase (DPD) catabolises more than 80% of 5-FU, a uracil threshold of 16 ng/mL has been considered as partial DPD deficiency.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
